

Results of Extraordinary General Meeting

Sydney, Australia - 3 October 2023: Cannabis focused drug development and product innovation company Bod Science Limited ("Bod" or "the Company") (ASX: BOD) advises that, in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), Resolutions 1 to 4 set out in the Notice of Meeting lodged on the ASX on 31 August 2023 were duly passed by the requisite majority by a poll at the Extraordinary General Meeting of the Company held today.

Details of the voting results and proxies in respect of the resolutions are set out in the attached summary.

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson **Amalie Schreurs** Chief Executive Officer White Noise Communications Info@bodaustralia.com amalie@whitenoisecomms.com +61 2 9199 5018 +61 431 636 033





BOD SCIENCE LIMITED

RESULT OF EXTRAORDINARY GENERAL MEETING (ASX REPORT)

EXTRAORDINARY GENERAL MEETING Tuesday, 3 October, 2023

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	RATIFICATION OF ISSUE OF SHARES UNDER THE UNCONDITIONAL PLACEMENT	NA	18,825,281 94.59%	843,671 4.24%	233,614 1.17%	2,087,257	31,086,224 97.36%	843,671 2.64%	2,087,257	Carried
2	RATIFICATION OF ISSUE OF OPTIONS UNDER THE UNCONDITIONAL PLACEMENT	NA	18,648,100 93.67%	1,027,196 5.16%	233,614 1.17%	2,080,913	30,909,043 96.78%	1,027,196 3.22%	2,080,913	Carried
3	APPROVAL TO ISSUE SHARES AND OPTIONS TO MR DAVID BAKER UNDER THE DIRECTOR PLACEMENT	NA	23,178,536 93.58%	1,358,500 5.48%	230,514 0.93%	191,108	35,736,379 96.34%	1,358,500 3.66%	191,108	Carried
4	RATIFICATION OF ISSUE OF BROKER OPTIONS TO THE LEAD MANAGER	NA	27,895,223 95.36%	1,126,669 3.85%	230,514 0.79%	206,252	40,453,066 97.29%	1,126,669 2.71%	206,252	Carried

^{** -} Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item